Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 146 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypogonadism, Male Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism

NCT01446042
View directory record Official record
Conditions
Male Hypogonadism
Interventions
Testosterone
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
30
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 3 Interventional

Open-Label Extension Study of Setmelanotide

NCT06596135
View directory record Official record
Conditions
Obesity Associated With Defects in Leptin-melanocortin Pathway
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • San Diego, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 2 Interventional Results available

Oral Testosterone for the Treatment of Hypogonadism in Males

NCT02222558
View directory record Official record
Conditions
Hypogonadism
Interventions
TSX-002
Drug
Lead sponsor
TesoRx Pharma, LLC
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 30, 2016 · Synced Oct 2, 2026, 5:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prevalence of Hypogonadism in Male Cancer Patients

NCT00472940
View directory record Official record
Conditions
Cancer, Hypogonadism
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 2, 2026, 5:56 AM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

NCT06299891
View directory record Official record
Conditions
Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo
Drug · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 28 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 2, 2026, 5:56 AM EDT
Recruiting Phase 2 Interventional

Testosterone Treatment in Men With Chronic Kidney Disease

NCT05249634
View directory record Official record
Conditions
Hypogonadism, Male, Kidney Disease, Chronic
Interventions
Jatenzo Pill
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

NCT01438073
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Healthy Postmenopausal Women, Agonadism
Interventions
kisspeptin 112-121, GnRH
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

NCT01403116
View directory record Official record
Conditions
Male Hypogonadism
Interventions
Oral testosterone undecanoate, topical testosterone gel
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
Birmingham, Alabama • Calera, Alabama • Huntsville, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function

NCT01923870
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 25 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 2, 2026, 5:56 AM EDT
Terminated No phase listed Observational

Fertility Assessment in Patients With Klinefelter Syndrome

NCT02461303
View directory record Official record
Conditions
Klinefelter Syndrome
Interventions
Counseling
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 25 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

NCT02274181
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
19 Years to 60 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetic Study of Testosterone Enanthate

NCT01887418
View directory record Official record
Conditions
Hypogonadism
Interventions
QuickShot™ - 50 mg Treatment B, QuickShot™ - 100 mg Treatment A, Delatestryl 200 mg IM Treatment C
Drug
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 2, 2026, 5:56 AM EDT
Withdrawn No phase listed Observational

Adaptive Behavior Assessment of Men With 49, XXXXY, Klinefelter Syndrome

NCT00347464
View directory record Official record
Conditions
Klinefelter Syndrome
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
2 Years to 21 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride

NCT00400335
View directory record Official record
Conditions
Hypogonadism, Hypogonadism, Male
Interventions
Nanomilled testosterone, commercially available dutasteride, Nanomilled dutasteride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 2 Interventional

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

NCT06046443
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
LB54640, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 2, 2026, 5:56 AM EDT
Not listed Phase 2 Interventional

Pulsatile GnRH in Anovulatory Infertility

NCT00383656
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Amenorrhea, Kallmann's Syndrome
Interventions
GnRH, Pump
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 3 Interventional

Prevention of Osteoporosis in Men With Prostate Cancer

NCT00048841
View directory record Official record
Conditions
Prostate Cancer, Osteoporosis, Hypogonadism
Interventions
alendronate
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years to 85 Years · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 2, 2026, 5:56 AM EDT
Completed No phase listed Observational

Cardiometabolic Profiles of Boys With Klinefelter Syndrome

NCT02723305
View directory record Official record
Conditions
Klinefelter Syndrome, 47,XXY, Sex Chromosome Aneuploidy, XXY Syndrome
Interventions
No intervention
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 17 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 2, 2026, 5:56 AM EDT
Recruiting No phase listed Observational

The eXtroardinarY Babies Study: Natural History of Health and Neurodevelopment in Infants and Young Children With Sex Chromosome Trisomy

NCT03396562
View directory record Official record
Conditions
Klinefelter Syndrome, Trisomy X, XYY Syndrome, XXXY and XXXXY Syndrome, Xxyy Syndrome, Xyyy Syndrome, Xxxx Syndrome, Xxxxx Syndrome, Xxxyy Syndrome, Xxyyy Syndrome, Xyyyy Syndrome, Male With Sex Chromosome Mosaicism
Interventions
Assessments of Development and Growth
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Weeks to 13 Months
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 2, 2026, 5:56 AM EDT
Not listed Not applicable Interventional

Baselines in Reproductive Disorders

NCT00456274
View directory record Official record
Conditions
Amenorrhea, Hypogonadotropic Hypogonadism, Kallmann's Syndrome
Interventions
Frequent baseline blood sampling
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Oct 2, 2026, 5:56 AM EDT
Completed No phase listed Observational

Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA

NCT02109770
View directory record Official record
Conditions
Microdeletion Syndromes, Trisomy 21, Trisomy 18, Trisomy 13, Sex Chromosome Abnormalities
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
Not listed
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
San Carlos, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Subcutaneous Testosterone Enanthate

NCT02233751
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone enanthate auto-injector
Combination Product
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 1 Interventional

Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)

NCT00392756
View directory record Official record
Conditions
Kallmann Syndrome, Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions
gonadotropin releasing hormone (GnRH)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males

NCT02149264
View directory record Official record
Conditions
Adult Male Hypogonadism
Interventions
Testosterone gel (FE 999303)
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
22
States / cities
Anniston, Alabama • Huntsville, Alabama • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 2, 2026, 5:56 AM EDT